Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05093621 · ClinicalTrials.gov registry record · Phase 3
Torsemide Comparison With Furosemide for Management of Patients With Stable Heart Failure
A Phase 3 study of Heart Failure, sponsored by Yale University.
- Completed
- Registry status
- Phase 3
- Development phase
- 47
- Enrollment target
- 1
- Study location
NCT05093621 is a Phase 3 study of Heart Failure that has completed, run by Yale University. The registered enrollment target is 47 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05093621, a Phase 3 study of Heart Failure, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is designed to be a prospective, randomized study is to compare the effectiveness of two standard of care loop diuretics (furosemide versus torsemide) on clinical outcomes among patients currently on a stable dose of loop diuretics.
Conditions Studied
Interventions
- DRUG Furosemide
- DRUG Torsemide
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2021-02-08 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05093621
The ClinicalTrials.gov registry entry for NCT05093621 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (98% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Furosemide is the first listed.
NCT05093621 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT05093621 about?
NCT05093621 is a clinical study titled "Torsemide Comparison With Furosemide for Management of Patients With Stable Heart Failure". The study is designed to be a prospective, randomized study is to compare the effectiveness of two standard of care loop diuretics (furosemide versus torsemide) on clinical outcomes among patients currently on a stable dose of loop diuretics.
What is the current status of trial NCT05093621?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 47 participants. The study started on 2021-02-08. Estimated completion is 2023-06-30.
What conditions does trial NCT05093621 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT05093621?
The interventions under investigation include: Furosemide (DRUG), Torsemide (DRUG).
Who is sponsoring clinical trial NCT05093621?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05093621 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Home-based Cardiac Rehabilitation in Heart Failure
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
RECRUITING · Phase 3
-
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
RECRUITING · Phase 3
-
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.